RNS Number : 8726K
BiVictriX Therapeutics PLC
31 August 2023
 

 

BiVictriX Therapeutics plc

("BiVictriX" or the "Company")

 

Total Voting Rights

 

 

Alderley Park, UK, 31 August 2023: BiVictriX Therapeutics plc, an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 82,526,088 ordinary shares of 1 pence each with voting rights.

The total number of voting rights in the Company is 82,526,088 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company.

 

ENDS

 

For more information, please contact:

 

BiVictriX Therapeutics plc


Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman

 

 

 

Email: info@bivictrix.com



SP Angel Corporate Finance LLP (NOMAD and Broker)

Tel: +44 (0) 20 3470 0470


David Hignell, Kasia Brzozowska (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)



 

Panmure Gordon (UK) Limited (Joint Broker)

 

Tel: +44 (0) 20 7886 2500


Rupert Dearden/Freddy Crossley/Emma Earl

 

Consilium Strategic Communications


Mary-Jane Elliott, Namrata Taak,

Max Bennett, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com




 

About BiVictriX Therapeutics plc

 

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

 

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAEPEDLEDEAA